IRS-2 G1057D polymorphism in Turkish patients with colorectal cancer

Emel Hulya Yukseloglu¹, Sevim Karakas Celik², Meral Urbhan Kucuk³, Erdinc Yalin⁴, S. Sebnem Ozkal⁵, Cengiz Ates⁶, Mehmet Berkoz⁷, Serap Yalin⁸, Nurcan Aras Ates⁹

¹Institute of Forensic Sciences, Istanbul University, Cerrahpasa, Istanbul, Turkey
²Department of Medical Biology and Genetics, Medical Faculty, Bulent Ecevit University, Zonguldak, Turkey
³Department of Biology, Faculty of Art and Science, Adiyaman University, Adiyaman, Turkey
⁴Department of Biochemistry, Medical Faculty, Cukurova University, Adana, Turkey
⁵Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Yeni Yuzyil University, Istanbul, Turkey
⁶General Surgery, Toros Government Hospital, Mersin, Turkey
⁷Department of Pharmaceutical Biotechnology, Pharmacy Faculty, Yuzuncu Yil University, Van, Turkey
⁸Department of Biochemistry, Pharmacy Faculty, Mersin University, Mersin, Turkey
⁹Department of Medical Biology and Genetics, Medical Faculty, Mersin University, Mersin, Turkey

Key words: IRS-2, colon cancer, polymorphism, Turkey.

Introduction: Gene polymorphisms have a broad range of analysis, but are of particular use in molecular medicine due to their potential in revealing the genetic tendency in diseases such as cancer, heart attack etc. These studies basically depend on mutations that can be detected by proper techniques. The genes coding the insulin receptor substrate (IRS) proteins are among the most widely analysed polymorphisms in various cancer types, in which a G1057D mutation is seen.

Aim: To determine the risk of colon cancer by analysing the IRS-2 gene polymorphism in Turkish patients.

Material and methods: A total of 161 newly diagnosed colorectal cancer patients were analysed and compared to 197 unrelated healthy controls. A polymerase chain reaction-based restriction fragment length polymorphism method was carried out.

Results: No differences were observed between the patient and control groups for both allele and genotype frequencies of the IRS-2 G1057D gene.

Conclusions: Our results demonstrated that IRS-2 G1057D polymorphism is not associated with colorectal cancer in the Turkish population. This research is a preliminary and original study in Turkish patients with colorectal cancer. It also provides population-level genetic data on IRS-2 in the Turkish population. Further studies should be performed on larger number of patients and controls for more reliable results about the genetic tendency in colorectal cancer in Turkey. The study is a collaborative work of different universities and scientists.

Introduction

Cancer is the primary cause of death in the world. Among the different cancer types, colon cancer is the fourth most frequently seen and the fourth most frequent cause of death. Every year 677,000 people die because of colon cancer [1]. Colorectal cancer or colon cancer is described as the cancer type occurring in colon tissues, which form the longest part of the large intestine. Most colon cancers are adenocarcinomas that begin at the cells producing and secreting mucus and other fluids [2]. Colorectal adenomas or adenocarcinomas are the first phase of the pathological transformation of normal colon epithelial cells to colorectal cancer cells [3].

About 95% of colorectal cancers occur at irregular intervals, which infers that the genes are damaged by chance. The rest (about 5%) are transmitted genetically and are less common [2]. Although the factors that can influence the risk of cancer are not precisely known, some environmental and genetic factors are considered to be effective. Research is ongoing on this issue. Diet,
anti-nonsteroidal anti-inflammatory drugs (NSAIDs), smoking and physical activity are some of the environmental agents being studied [2]. There are several studies revealing that physiological differences such as hormone levels are also determinants of breast, prostate, colorectal and lung cancers [3–5]. For example, the interruption of the connection of insulin secretion and function results in hyperinsulinemia, hyperglycaemia and type 2 diabetes. Hyperinsulinemia and type 2 diabetes increase the risk of colon cancer [6]. Insulin-like growth factor (IGF), insulin-like growth factor binding proteins (IGFBPs), insulin and insulin receptor substrate (IRS) play significant roles in the initiation of cell growth and colorectal cancer proliferation [4, 7, 8]. Studies linking insulin resistance, obesity and colorectal cancer suggest that the insulin pathway may play an important role in the aetiology of colorectal cancer [9–11]. IRS proteins are IRS-1 and IRS-2, which are very common, IRS-3 found mostly in adipose tissues, and IRS-4 in the thymus, brain and kidney [12].

The genes expressing the proteins have recently been studied to analyse the gene polymorphisms in different populations, due to their clinical significance as some of the polymorphic genes will produce polymorphic proteins, whose functions in the body might be affected and clinical diseases might occur. Therefore scientists are researching the gene polymorphisms and the clinical outcomes in order that the genetic tendency of the medical conditions could be specified and diagnostic–prognostic markers could be represented [13].

The gene encoding the insulin receptor substrate 2, IRS-2 gene, will only be discussed here due to the concept of the paper. Several polymorphisms have been identified in the IRS-2 gene, but in humans the prevalent polymorphism is Gly1057Asp, which is also known as G1057D single nucleotide polymorphism (SNP) (rs1805097). The genotypes of this SNP (GG, GD and DD) are analysed by means of their frequency in various patients and control groups in order to specify the association between IRS-2 G1057D polymorphism and clinical diseases. For instance, Slattery et al. [14] showed that IRS-1 (G972D) and IRS-2 (G1057D) gene polymorphisms have coherent and independent effects in colon cancer. Studies on gene polymorphisms in colorectal cancer, which have been conducted around the world, have to be initiated also in Turkey; this would allow analysis of the genetic tendency in colorectal cancer.

**Aim**

This study aims to investigate whether IRS-2 G1057D gene polymorphism is associated with colorectal cancer in Turkish patients.

**Material and methods**

**Subjects**

This study includes all cases of colorectal cancer consecutively hospitalised in the Surgery Departments of Mersin and Kocaeli University Hospitals, including patients initially seen as outpatients, from September 2001 through April 2004. The 161 newly diagnosed colorectal cancer patients and 197 unrelated healthy controls were recruited from two hospitals in Turkey. The study was approved by the ethics committees of the institutions involved in this research.

**IRS-2 genotyping**

Genomic DNA was extracted from 200 μl of peripheral blood by High Pure DNA isolation Kit (Qiagen, Inc., Chatsworth, CA) following then manufacturer’s instructions. A polymerase chain reaction (PCR)-based restriction fragment–length polymorphism (RFLP) method was used for genotype IRS-2 G1057D polymorphism, which removes the Hae-II restriction enzyme site. The PCR was performed in a 25 μl volume containing 20 ng genomic DNA, 10×PCR buffer with 1.5 mM MgCl₂, 0.25 mM dNTPs, 10% dimethylsulphoxide, 0.5 units of Taq polymerase (Fermantas, MBI) and 5 pmol of each primer, IRS-2F (5’ GCT CCC CCA AGT CTC CTA A 3’) and IRS-2R (5’ CTC AGC CTC TTC ACG CCC 3’). The PCR thermal cycling conditions were an initial melting period at 95°C for 2 min; then 35 amplification cycles of 95°C for 45 s, 62°C for 45 s and 72°C for 45 s; and a 7-minute extension step at 72°C. The PCR products were checked on 1.5% agarose gel for the assay completion, and then the PCR products of 375 base pairs (bp) were digested with restriction enzyme Hae-II by overnight incubation at 37°C. The digestion products were electrophoresed on 3% agarose gel and visualised by staining with ethidium bromide and evaluated using the gel documentation system (Vilber-Lourmat, Cedex, France).

**Statistical analysis**

A case-control study was performed and allelic frequency of the polymorphism was calculated both in cases and controls. The χ² test was used to compare the genotype frequency of the IRS-2 gene polymorphism between colorectal cancer patients and controls. The association between IRS-2 polymorphisms and colorectal cancer was modelled through binary logistic regression analysis. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated to compare colorectal cancer risk for the genotypes. Values of \( p \leq 0.05 \) was considered as the significance level. The software used for the calculation was SPSS version 11.5 (SPSS Inc., Chicago, IL).
Results

A total of 161 patients with colorectal cancer (male : female = 94 : 67; mean age: 59.91 ±13.26 years) and 197 control subjects (male : female = 95 : 102; mean age: 57.11 ±14.60 years) participated in this study. Age and gender data of both groups are shown in Table I.

As shown in Table II, the frequencies of GG, GD and DD were 49.1%, 36.0% and 43.1% in cases and 44.7%, 43.1% and 12.2%, respectively, in controls for IRS-2 G1057D polymorphism. No difference was found between the genotypes in groups (p > 0.05; Table II). The frequency of G allele was 0.671 for cases and 0.662 for controls, whereas the frequency of D allele was 0.329 for cases and 0.338 for controls. There was also no difference between cases and controls for the frequency of G and D alleles (p > 0.05; Table II).

Discussion

Insulin, the hormone that controls the energy homeostasis by functioning on target tissues such as liver, muscle and adipose, acts as if being attached to its receptors on the cell membrane. The insulin receptors phosphorylate the polymorphic substrate proteins, called insulin receptor substrates. IRS proteins, particularly IRS-1 and IRS-2, are present in almost all cells and tissues. IRS-1 controls body growth and peripheral insulin action, whereas IRS-2 regulates body weight control and glucose homeostasis [14].

The levels of IRS proteins were examined in pancreatic cancer [3] and breast cancer [5, 7], whereas Keku et al. [6] studied insulin, glucose, IGF and IGFBP levels, and Wei et al. [15] studied C-peptide, IGFBP-1 and haemoglobin levels in colorectal adenoma cases.

There are several pieces of evidence indicating that insulin is associated with the risk of colorectal cancer [9, 16]. In rats, insulin enhances the growth of aberrant crypt foci and colorectal cancer precursor lesions, and increases the number and the size of the tumours [9].

Several studies have also found a link between insulin, type 2 diabetes, obesity and body size and the risk of colorectal cancer [9–11, 17]. There is also evidence for the association between elevated levels of insulin and increased risk of colorectal cancer in humans [17, 18].

The gene polymorphisms coding the IRS proteins were comprehensively studied by means of diseases such as polycystic ovary syndrome [19], obesity [20], type 2 diabetes [21], prostate cancer [22], breast cancer [8], gastric cancer [23], ovarian cancer [24] and colon cancer [14, 25, 26]. Tumour size, lymph nodes and metastasis are widely examined in cancer research studies; however, only specific genes that are known to play a role in tumour initiation, progression and metastasis are analysed to identify the relevance of tumour characteristics. For instance, Röcken et al. [27] showed that an enzyme that participates locally in the pathology of carcinoma, angiotensin I–converting enzyme (ACE), gene polymorphism was associated with gender-specific differences in primary tumour size. However, the IRS gene polymorphisms have not yet been studied regarding tumour size, lymph nodes and even metastasis.

Most of the research regarding IRS-2 G1057D polymorphism has been detected using PCR and certain

Table I. The distribution of patients and controls by age and gender

| Parameter | Patients | Controls | Value of p |
|-----------|----------|----------|------------|
| Total number | 161 | 197 | |
| Age, mean ±SD [years] | 59.91 ±13.26 | 57.11 ±14.60 | 0.06 |
| Gender: | | | 0.06 |
| Female, n (%) | 67 (41.6) | 102 (51.8) | |
| Male, n (%) | 94 (58.4) | 95 (48.2) | |

n – number of sample

Table II. IRS-2 genotype and allele frequencies of patients and controls

| Variable | Patients (N = 161) | Controls (N = 197) | Odds ratio | 95% CI |
|----------|------------------|------------------|------------|--------|
| Genotype: | | | | |
| GG | 79 (49.1) | 88 (44.7) | 1 (reference)* |
| GD | 58 (36.0) | 85 (43.1) | 0.76 | 0.48–1.19 |
| DD | 24 (14.9) | 24 (12.2) | 1.11 | 0.58–2.11 |
| Allele: | | | | |
| G | 216 (67.1) | 261 (66.2) | 1 (reference)* |
| D | 106 (32.9) | 133 (33.8) | 1.50 | 0.99–2.29 |

n – number of sample, 95% CI (95% confidence interval) from conditional logistic regression. *Carriers of at least one intact allele are used as reference
IRS-2 G1057D polymorphism in Turkish patients with colorectal cancer

Subsequent enzyme digestions; Gunter et al. [26] used SNP selection to analyse this polymorphism. It was detected that none of the IRS-2 polymorphisms were related to colorectal adenoma.

IRS-2 G1057D polymorphism also lies close to two putative phosphorylation tyrosine sites; however, no effect of its binding ability to the p85 subunit of PI-3 kinase has been observed [28]. Similar to IRS-1, several studies showing inconsistent effects of IRS-2 SNP have been observed in insulin resistance-related diseases [29]. No association has been detected in studies regarding prostate cancer [22], breast cancer [28], type 2 diabetes and obesity [30]. In the study of Slattery et al. [14], heterozygotes, but not the homozygotes, for the D allele were shown to be at reduced risk of colorectal cancer. Pechlivanis et al. [31] showed that IRS-2 G1057D polymorphism was not associated with the risk of colorectal cancer.

Colon cancer risk also affects specific types of mutations. Samowitz et al. [25] analysed 1788 cases and 1981 controls for IRS-1, IRS-2, IGF-1 and IGFBP-3 as well as tumour mutations and microsatellite instability. Only the heterozygous genotype of IRS-2 GD was determined to be related to a decreased risk of microsatellite instability.

So far, there have been various studies and data regarding IRS-2 G1057D polymorphism in the world. No information is available for this polymorphism among Turkish colon cancer patients. We report herein the genotype and allele frequencies of this polymorphism and the role of IRS-2 G1057D polymorphism in colorectal cancer susceptibility in patients and healthy subjects representing the Turkish population. For IRS-2 G1057D polymorphism, the frequencies of GG, GD, and DD genotypes were 49.1%, 36.0% and 14.9% in cases and 44.7%, 43.1% and 12.2% in controls, respectively. Slattery et al. [14] studied 1181 colon cancer cases and 1194 controls. The frequencies of GG, GD, and DD genotypes were 46.5%, 40.7% and 12.8% in cases and 41.2%, 47.3% and 11.5% in controls, respectively. Slattery et al. [14] detected that the GD genotype is related to a reduced risk in colon cancer. Samowitz et al. [25] studied 1788 colon cancer cases and 1981 controls. They observed GD genotype as 45.7% in cases (42.2% in controls), GD was 41.8% in cases (46.1% in controls) and DD was 12.5% in cases (11.7% in controls). When compared to our study, there is not a significant difference in the frequencies of the genotypes analysed. The increase of heterozygote individuals in both studies of Slattery [14] and Samowitz [25] might be due to the large sample group size. Recently, Cayan et al. [24] examined the association of IRS-2 gene polymorphism with ovarian cancer in 185 Turkish women and found the GG genotype to be 53.6%; GD 38.6% and DD 7.9% in the control group, whereas our control results were 44.7%, 43.1% and 12.2%, respectively.

The frequency of G allele was 0.671 for cases and 0.662 for controls in our study. The frequency of D allele was 0.329 for cases and 0.338 for controls. Slattery et al. [14] determined that the IRS-2 G allele frequencies were 0.568 and 0.658, and D allele frequencies were 0.281 and 0.342 for cases and controls, respectively. Samowitz et al. [25] observed that the IRS-2 G allele frequencies were 0.585 and 0.476, and D allele frequencies were 0.294 and 0.515 for cases and controls, respectively. The decrease in the allele frequencies of IRS-2 G1057D polymorphism when compared to our study might also be due to the size of the groups. For healthy control groups, Cayan et al. [24] specified that the IRS-2 G allele frequency was 0.729, and D allele frequency was 0.271 in a Turkish population, whereas our control results were 0.662 and 0.338, respectively.

Conclusions

The results obtained from the current study demonstrate that IRS-2 G1057D polymorphism is not a susceptible factor for colorectal cancer in Turkish patients. This research is a preliminary study in Turkish patients with colorectal cancer. It also provides population-level genetic data on IRS-2 in the Turkish population. Further studies should be performed on a larger number of patients and controls for more reliable results regarding the genetic tendency in colorectal cancer in Turkey.

References

1. World Health Organization, Health Statistics and Health Information Systems Website: http://www.who.int/healthinfo/statistics/en/ [15 September 2012].
2. National Cancer Institute, Genetics of Colorectal Cancer Website: http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/healthprofessional/allpages/print [19 September 2012].
3. Kornmann M, Maruyama H, Bergmann U, et al. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res 1998; 58: 4250-4.
4. Fürstenberger G, Senn HJ. Insulin-like growth factor and cancer. Lancet Oncol 2002; 3: 298-302.
5. Cui X, Kim HJ, Kuiatse I, et al. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 2006; 66: 5304-13.
6. Keku TO, Lund PK, Galanko J, et al. Insulin resistance, apoptosis and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2076-81.
7. Jackson JG, Zhang X, Yoneda T, et al. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001; 20: 7318-25.
8. Slattery ML, Sweeney C, Wolff R, et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women
living in Southwestern United States. Breast Cancer Res Treat 2007; 104: 197-209.

9. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109-20.

10. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiologic evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.

11. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68: 123-58.

12. Burks DJ, de Mora JF, Schubert M, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000; 407: 377-82.

13. Cardoso J, Boer J, Morreau H, Fodde R. Expression and genomic profiling of colorectal cancer. BBA-Rev Cancer 2007; 1775: 103-37.

14. Slattery ML, Samowitz W, Curtin K, et al. Associations among IRS1, IRS2, IGF1 and IGFBP3 Polymorphisms and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1206-14.

15. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006; 15: 750-5.

16. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80.

17. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91: 1147-54.

18. Ehrman DA, Tang X, Yoshiuchi I, et al. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4297-300.

19. Lautier C, El Mkadem SA, Renard E, et al. The gene polymorphism of the angiotension I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 2007; 9: 716-22.

20. Wagner K, Hemminki K, Forsti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 2007; 104: 233-48.

21. Neuhausen SL, Samowitz W, Garner CP, et al. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. Prostate 2005; 64: 168-74.

22. Zhao XM, Chen J, Yang L, et al. Association between IRS-2 G1057D polymorphism and risk of gastric cancer. World J Gastrointest Oncol 2012; 4: 9-15.

23. Ouederni BT, Sanchez-Corona J, Martinez SEF, et al. The G1057D polymorphism of IRS-2 gene is not associated with type 2 diabetes and obese patients among ethnic groups in Tunisian population. Clin Biochem 2009; 42: 1169-73.

24. Pechlivanis S, Pardini B, Bermejo JL, et al. Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer 2007; 14:733-40.

Received: 12.04.2013
Accepted: 8.08.2013